[FGEN] FibroGen, Inc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 20.8 Change: 1.3 (6.67%)
Ext. hours: Change: 0 (0%)

chart FGEN

Refresh chart

Strongest Trends Summary For FGEN

FGEN is in the long-term up 87% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 19.29% Sales Growth - Q/Q1.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.33% ROE-73.92% ROI-45.95%
Current Ratio2.88 Quick Ratio Long Term Debt/Equity0.95 Debt Ratio0.29
Gross Margin Operating Margin-281.76% Net Profit Margin-296.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities620 K Cash From Investing Activities4.55 M Cash From Operating Activities-42.19 M Gross Profit
Net Profit-46.37 M Operating Profit-44.72 M Total Assets435.54 M Total Current Assets155.4 M
Total Current Liabilities53.96 M Total Debt111.65 M Total Liabilities250.92 M Total Revenue16.3 M
Technical Data
High 52 week67.25 Low 52 week35.14 Last close35.77 Last change-4.15%
RSI26.06 Average true range2.86 Beta1.53 Volume241.17 K
Simple moving average 20 days-18.87% Simple moving average 50 days-27.97% Simple moving average 200 days-30.35%
Performance Data
Performance Week-1.7% Performance Month-22.48% Performance Quart-38.85% Performance Half-12.05%
Performance Year-32% Performance Year-to-date-22.71% Volatility daily5.57% Volatility weekly12.46%
Volatility monthly25.54% Volatility yearly88.49% Relative Volume223.58% Average Volume843.49 K
New High New Low


2019-10-16 08:45:12 | 5 Stocks With High Net Income Ratio to Scoop Up

2019-10-11 10:58:45 | Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease CKD Anemia to be Presented at American Society of Nephrology Kidney Week 2019

2019-10-07 17:57:46 | FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

2019-10-07 06:41:15 | UK and US scientists win Nobel Medicine Prize

2019-10-03 10:59:02 | FibroGen Enters Oversold Territory

2019-10-03 09:42:01 | Heron Therapeutics HRTX Catches Eye: Stock Jumps 6.2%

2019-09-30 20:00:00 | FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat

2019-09-30 07:00:00 | FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

2019-09-27 11:03:03 | FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia

2019-09-26 11:16:03 | Tyme Initiates Pivotal Stage of Pancreatic Cancer Study

2019-09-26 09:00:01 | BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

2019-09-26 07:00:00 | FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

2019-09-25 08:34:12 | Dova Pharmaceuticals DOVA Jumps: Stock Rises 8.8%

2019-09-23 13:20:05 | Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

2019-09-23 12:36:04 | Zoetis ZTS Receives EC Approval for Simparica Trio in Dogs

2019-09-20 11:54:03 | FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD

2019-09-20 03:05:58 | Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

2019-09-20 03:00:00 | Evrenzo® roxadustat Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

2019-09-18 08:13:13 | Is FibroGen, Inc.'s NASDAQ:FGEN 7.6% ROE Worse Than Average?

2019-09-13 11:38:03 | Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ

2019-09-12 08:40:12 | What Makes Crinetics Pharmaceuticals CRNX a Strong Sell?

2019-09-12 07:08:11 | 5 Stocks with High Net Income Ratio to Grab Now

2019-09-10 11:46:03 | Theravance Announces Positive Early Data on JAK Inhibitor

2019-09-10 04:56:08 | Endo Files BLA for CCH With the FDA for Cellulite Candidate Revised

2019-09-09 09:50:01 | Endo International Files BLA for Label Expansion of Xiaflex

2019-09-03 08:35:12 | Radius RDUS Catches Eye: Stock Jumps 6.8%

2019-08-29 09:50:01 | Ensign Group to Spin Off Home Health & Hospice Business

2019-08-27 09:00:01 | FibroGen FGEN Catches Eye: Stock Jumps 7.4%

2019-08-26 19:33:30 | FibroGen CEO Thomas Neff dies suddenly as company drives toward first FDA drug approval

2019-08-26 08:30:00 | Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

2019-08-23 18:15:11 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.8 million of Shares

2019-08-22 18:08:10 | AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

2019-08-22 07:18:53 | The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

2019-08-21 16:11:00 | Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis

2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta

2019-08-19 17:55:09 | Nabriva NBRV Aims to Resubmit Contepo NDA in Q4

2019-08-15 01:15:29 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.8 million of Shares

2019-08-14 09:51:01 | Tilray TLRY Catches Eye: Stock Jumps 8.4%

2019-08-13 09:44:22 | FibroGen NASDAQ:FGEN Has A Pretty Healthy Balance Sheet

2019-08-09 23:07:18 | FibroGen Inc FGEN Q2 2019 Earnings Call Transcript

2019-08-09 17:03:26 | Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-08 20:00:12 | FibroGen FGEN Q2 Earnings and Revenues Top Estimates

2019-08-01 20:39:45 | CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-08-01 19:24:01 | FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-07-30 10:38:02 | Earnings Preview: FibroGen FGEN Q2 Earnings Expected to Decline

2019-07-26 19:15:02 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.9 million of Shares

2019-07-24 18:53:26 | Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine NEJM

2019-07-24 18:53:22 | The New England Journal of Medicine NEJM Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis

2019-07-22 07:00:00 | FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

2019-07-10 06:00:56 | Shareholders Are Thrilled That The FibroGen NASDAQ:FGEN Share Price Increased 165%